Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Corsetti, James P ^a   Bakker, Stephan J L ^b   Sparks, Charles E ^a   Dullaart, Robin P F ^b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A2; APOLIPOPROTEIN E; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION RESEARCH; PREDICTION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; APOLIPOPROTEIN A-II; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK;

EID: 84862499644     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039110     Document Type: Article

References (64)

1. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP, (2008) Multiple actions of high-density lipoprotein. Curr Opin Cardiol 23: 370-378.
2. deGoma EM, deGoma RL, Rader DJ, (2008) Beyond high-density lipoprotein cholesterol levels. J Am Coll Cardiol 51: 2199-2211.
3. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P, (2008) Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 15: 52-62.
4. Ragbir S, Farmer JA, (2010) Dysfunctional high-density lipoprotein and atherosclerosis Curr Atheroscler Rep 12: 343-348.
5. Shao B, Oda M, Oram JF, Heinecke JW, (2010) Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 23: 447-454.
6. Ansell BJ, Fonarow GC, Fogelman AM, (2007) The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 18: 427-434.
7. Kontush A, Chapman MJ, (2006) Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacological Reviews 58: 342-374.
8. Onat A, Hergene G, (2011) Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiovascular risk. Metabolism Clinical and Experimental 60: 499-512.
9. De Backer G, de Bacquer D, Kornitzer M, (1998) Epidemiological aspects of high density lipoprotein cholesterol. Atherosclerosis.
10. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F, (1998) Triglyceride concentration and ischemic heart disease. Circulation 97: 1029-1036.
11. von Eckardstein A, Schulte H, Assmann G, (1999) Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol. Circulation 99: 1925.
12. Bittner V, Simon JA, Fong J, Blumenthal RS, Newby K, et al. (2000) Correlates of high HDL cholesterol among women with coronary heart disease. Am Heart J 139: 288-296.
13. Shimoni N, Kaplan M, Keidar S, (2003) Cardiovascular diseases in patients with high levels of plasma high density lipoprotein: association with increased plasma oxidative state. Israel Med Association J. 5: 702-705.
14. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A, (2000) Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 101: 1907-1912.
15. Gnasso A, Motti C, Irace C, Di Gennaro I, Pujia A, et al. (2002) The ARG allele in position 192 of PON1 is associated with carotid atherosclerosis in subjects with elevated HDLs. Atherosclerosis 164: 289-295.
16. deLemos AS, Wolfe ML, Long CJ, Sivapackianathan R, Rader DJ, (2002) Identification of genetic variants in endothelial lipase in persons with elevated High-Density Lipoprotein cholesterol. Circulation 106: 1321-1326.
17. Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, et al. (2003) Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. PNAS 100: 2748-2753.
18. Broedl UC, Jin W, Rader DJ, (2004) Endothelial lipase: a modulator of lipoprotein metabolism upregulated by inflammation. Trends Cardiovasc Med 14: 202-206.
19. Grundy SM, Vega GL, Otvos JD, Rainwater DL, Cohen JC, (1999) Hepatic lipase activity influences high density lipoprotein subclass distribution in normotriglyceridemic men: genetic and pharmacological evidence. J Lipid Res. 40: 229-234.
20. Ruel IL, Couture P, Cohn JS, Bensadoun A, Marcil M, et al. (2004) Evidence that hepatic lipase deficiency in humans is not associated with proatherogenic changes in HDL composition and metabolism. J Lipid Res 45: 1528-1537.
21. Corsetti JP, Gansevoort RT, Sparks CE, Dullaart RPF, (2010) HDL protection against primary cardiac risk is lost with inflammation. Eur J Clin Invest 40: 483-489.
22. Corsetti JP, Gansevoort RT, Navis GJ, Sparks CE, Dullaart RPF, (2011) LPL polymorphism (D9N) predicts cardiovascular disease risk directly and through interaction with CETP polymorphism (TaqIB) in women with high HDL cholesterol and CRP. Atherosclerosis 214: 373-376.
23. Corsetti JP, Gansevoort RT, Bakker SJL, Navis GJ, Sparks CE, et al. (2012) Apolipoprotein E predicts incident cardiovascular disease risk in women but not in men with concurrently high levels of high-density lipoprotein cholesterol and C-reactive protein. Metabolism (In press).
24. Corsetti JP, Ryan D, Rainwater DL, Moss AJ, Zareba W, et al. (2010) Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol 30: 1657-1664.
25. Corsetti JP, Ryan D, Moss AJ, Zareba W, Sparks CE, (2007) NAD(P)H oxidase polymorphism (C242T) and high HDL-C associate with recurrent coronary events in post infarction patients. Atherosclerosis 196: 461-468.
26. Blanco-Vaca F, Escola-Gil JC, Martin-Compos JM, Julve J, (2001) Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lip Res 42: 1727-1739.
27. Tailleux A, Duriez P, Fruchart JC, Clavey V, (2002) Apolipoprotein A-II, HDL metabolism and atherosclerosis. Atherosclerosis 164: 1-13.
28. Kalopissis AD, Pastier D, Chambaz J, (2003) Apoplipoprotein A-II: beyond genetic associations with lipid disorders and insulin resistance. Curr Opin Lipidol 14: 165-172.
29. Martin-Campos JM, Escola-Gil JC, Ribas V, Blanco-Vaca F, (2004) Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptilbility. Curr Opin Lipidol 15: 247-253.
30. Scanu AM, Edelstein C, (2008) HDL: bridging past and present with a look at the future. FASEB J 22: 4044-4054.
31. Dugue-Pujol S, Rousset X, Pastier D, Quang NT, Pautre V, et al. (2006) Human apolipoprotein A-II associates with triglyceride-rich lipoproteins in plasma and impairs their catabolism. J Lip Res 47: 2631-2639.
32. Julve J, Escola-Gil JC, Rotllan N, Fievet C, Vallez E, et al. (2010) Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler Thromb Vasc Biol 30: 232-238.
33. Brousseau ME, Millar JS, Diffenderfer MR, Nartsupha C, Asztalos BJ, et al. (2009) Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II containing HDL subspecies and apolipoprotein A-II metabolism. J Lip Res 50: 1456-1462.
34. Birjmohun RS, Dallinga-Thie GM, Kuivenhoven JA, Stroes ESG, Otvos JD, et al. (2007) Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation 116: 2029-2035.
35. Wroblewska M, Czyzewska M, Wolska A, Kortas-Stempak B, Szutowicz A, (2010) ApoA-II participates in HDL-liposome interaction by the formation of new pre-β mobility particles and the modification of liposomes. Biochim Biophys Acta 1801: 1323-1329.
36. Pinto-Sietsma SJ, Janssen WMT, Hillege HL, Navis G, De Zeeuw D, et al. (2000) Urinary albumin excretion is associated with renal functional abnormalities in a non-diabetic population. J Am Soc Nephrol 11: 1882-1888.
37. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, et al. (2008) Albuminuria assessd from first-morning-void urine samples versus 24 hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 168: 897-905.
38. Verhave JD, Gansevoort RT, Hillege HL, Bakker SJ, De Zeeuw D, et al. (2004) An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int 66: S18-S21.
39. Corsetti JP, Zareba W, Moss AJ, Sparks CE, (2005) Serum glucose and yriglyceride determine high-risk subgroups in non-diabetic postinfarction patients. Atherosclerosis 183: 293-300.
40. Borggreve SE, Hillege HL, Wolffenbuttel BHR, de Jong PE, Zuurman MW, et al. (2006) An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study. J Clin Endocrinol Metab 91: 3382-3388.
41. Huang R, Gangani SD, Jerome WG, Kontush A, Chapman MJ, et al. (2011) Apolipoprotein A-I structural organization in high-density lipoproteins isolated from human plasma. Nat Struct Mol Biol 18: 416-423.
42. Sich D, Saidi Y, Giral P, Lagrost L, Dallongeville J, et al. (1998) Characterization of two HDL subfractions and LpA-I, LpA-I:A-II distribution profiles and clinical characteristics of hyperalphlipoproteinemic subjects without cholesterol ester transfer protein deficiency. Atherosclerosis 138: 351-360.
43. Asztalos BF, Demissie S, Cupples LA, Collins D, Cox CE, et al. (2006) LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham Offspring Study and the Veterans Affairs HDL Intervention Trial. Atherosclerosis 188: 59-67.
44. Syvanne M, Kahri J, Virtanen KS, Taskinen MR, (1995) HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 92: 364-370.
45. Puchois P, Kandoussi A, Fievet P, Fourrier JL, Bertrand M, et al. (1987) Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 68: 35-40.
46. Boisfer E, Stengel D, Pastier D, Laplaud PM, Dousset N, et al. (2002) Anitoxidant properties of HDL in transgenic mice overexpressing human apolipoprotein A-II. J Lip Res 43: 732-741.
47. Ribas V, Sanchez-Quesada JL, Anton R, Camacho M, Julve J, et al. (2004) Human apolipoprotein A-II enrichment displaces paraoxonase form HDL and impairs its anti-oxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ Res 95: 789-797.
48. Castellani LW, Navab M, Van Lenten BJ, Hedrick CC, Hama SY, et al. (1997) Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest 100: 464-474.
49. Hedrick CC, Castellani LW, Wong H, Lusis AJ, (2001) In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions. J Lip Res 42: 563-570.
50. Thompson PA, Berbee JFP, Rensen PCN, Kitchens RL, (2008) Apolipoprotein A-II augments monocyte responses to LPS by suppressing the inhibitory activity of LPS-binding protein. Innate Immun 14: 365-374.
51. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, (1978) Apoprotein (E-A-II) complex of human plasma lipoproteins. J Biol Chem. 253: 6289-6295.
52. Weisgraber KH, Shinto LH, (1991) Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma. J Biol Chem. 266: 12029-12034.
53. Bekaert ED, Alaupovic P, Knight-Gibson C, Norum RA, Laux MJ, et al. (1992) Isolation and partial characterization of lipoprotein A-II (LP A-II) particles of human plasma. Biochim Biophys Acta 1126: 105-113.
54. Durbin DM, Jonas A, (1997) The effect of apoliprotein A-II on the structure and function of apolipoprotein A-I in a homogeneous reconstituted high density lipoprotein particle. J Biol Chem 272: 31333-31339.
55. Atmeh RF, (1990) Isolation and identification of HDL particles of low molecular weight. J Lipid Res 31: 1771-1780.
56. Harchaoui KE, Arsenalt BJ, Franssen R, Despres JP, Hovingh GK, et al. (2009) High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med 150: 84-93.
57. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, et al. (2009) Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 119: 931-939.
58. Kazlauskaite R, Powell LH, Mandapakala C, Cursio JF, Avery EF, et al. (2010) Vitamin D is associated with atheroprotective high-density lipoprotein profile in postmenopausal women. J Clin Lipidol 4: 113-119.
59. Leroy A, Toohill KLH, Fruchart JC, Jonas A, (1993) Structural properties of high density lipoprotein subclasses homogeneous in protein composition and size. J Biol Chem 268: 4798-4805.
60. Atmeh RF, Shepherd J, Packard CJ, (1983) Subpopulations of apolipprotein A-I in human high-density lipoproteins their metabolic properties and response to drug therapy. Biochim et Biophys Acta 751: 175-188.
61. Norfeldt PIP, Olofsson SO, Fager G, (1981) Isolation and partial characterization of the lipoprotein families A and A-I from high-density lipoproteins of human serum. Eur J Biochem 118: 1-8.
62. Ohta T, Hattori S, Nishiyama S, (1988) Studies on the lipid and apolipoprotein compositions of two species of apoA-I-containing lipoproteins in normolipidemic males and females. J Lip Res 29: 721-728.
63. Cheung MC, Albers JJ, (1984) Characterization of lipoprotein particles isolated by immunoaffinity chromatography. J Biol Chem 259: 12201-12209.
64. Mahley RW, (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-630.